Navigation Links
Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
Date:5/27/2009

- Oral Presentation to Highlight Data from Phase II Study Evaluating Bavituximab in Advanced Breast Cancer -

- Poster Presentation to Discuss Data from Phase I Study Evaluating Bavituximab in Multiple Tumor Types -

TUSTIN, Calif., May 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that data from two ongoing clinical trials assessing its lead compound bavituximab for the treatment of cancer will be discussed at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. Preliminary data from a Phase II clinical trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients will be the subject of an oral presentation at 10:30 AM EDT on June 1, 2009. A second presentation detailing preliminary results from a Phase I clinical trial evaluating bavituximab as solo therapy in patients with advanced refractory cancer will be discussed in a poster session from 1:00 PM to 5:00 PM EDT, also on June 1, 2009.

    Bavituximab Presentation Details:
    Title: Phase II study of bavituximab plus docetaxel in patients with
    locally advanced or metastatic breast cancer.
    Authors: D. Tabagari, G. Nemsadze, M. Jincharadze, M. Janjalia, J. Shan
    Time: Monday June 1, 10:30 AM
    Location: Level 4, Valencia Room, W415A
    Abstract No: 3005

    Title: Phase I study of bavituximab, a novel anti-phosphatidylserine
    monoclonal antibody in patients with advanced refractory cancer:
    Preliminary results.
    Authors: N. K. Ibrahim, L. Wong, L. Rosen, J. Shan
    Time: Monday June 1, 1:00 PM to 5:00 PM
    Location: Level 2, West Hall C
    Abstract No: 1080

About Bavituximab

Bavituximab is a monoclonal anti
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
4. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
5. Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies) Conference
6. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
7. goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites
8. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
9. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
10. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... On September 11, Pharma IQ conducted an interview with ... session that he will lead on “Stem Cells” at the ... 2015 in London. In the interview posted online ... respond to several questions on the current state of technologies ... toxicity, and future trends in the use of stem cells ...
(Date:9/29/2014)... 2014 Each year in the ... medical attention. In the military, burn injury is ... battlefield medical care. More than 800 service members ... wounds heal slowly, remain inflamed and often become ... debilitating and functionally damaging. While developments in supportive ...
(Date:9/29/2014)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") (OTC: ... that its three Promissory Note holders, two of whom ... each in July 2014 for a total of $ ... converted into 3,500,001 restricted common shares. Notes were repayable ... Note and the coupon were convertible into common shares ...
(Date:9/29/2014)... Transparency Market Research, in its report ... HPPS, by Application - Cancer, Metabolic, CVS, CNS & ... Delivery) - Global Industry Analysis, Size, Share, Growth, Trends ... peptide therapeutics market was worth US$14.1 billion in 2011 ... at an 8.7% CAGR. , The two main types ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3
... , , , , , , ... DNA per 450 l of supernatant processed. PLG tubes , also can be used ... , Grow a 10 ml stock of ... 0.5% yeast extract, 0.5% NaCl, 1 mM MgSO4, pH 7.5) overnight , ...
... , , , , , ... Katherine A. Borkovich PhD, University of Texas-Houston Medical Center, , ... and Molecular Genetics, Houston, Texas. , Kimberly Vollmer, Brinkmann™ ... , , , , , ...
... , , , Disposables such as ... to chemical reactions and they must withstand the various kinds , ... , and autoclaving). The stability level of these products ... they are made and this material's processing , during ...
Cached Biology Technology:Lambda DNA Extraction Protocol 2Efficient Transfection of Neurospora Crassa 2Efficient Transfection of Neurospora Crassa 3Efficient Transfection of Neurospora Crassa 4Efficient Transfection of Neurospora Crassa 5Chemical Stability of Disposables 2Chemical Stability of Disposables 3Chemical Stability of Disposables 4Chemical Stability of Disposables 5Chemical Stability of Disposables 6Chemical Stability of Disposables 7Chemical Stability of Disposables 8Chemical Stability of Disposables 9Chemical Stability of Disposables 10Chemical Stability of Disposables 11Chemical Stability of Disposables 12Chemical Stability of Disposables 13Chemical Stability of Disposables 14Chemical Stability of Disposables 15Chemical Stability of Disposables 16Chemical Stability of Disposables 17Chemical Stability of Disposables 18Chemical Stability of Disposables 19Chemical Stability of Disposables 20Chemical Stability of Disposables 21Chemical Stability of Disposables 22Chemical Stability of Disposables 23Chemical Stability of Disposables 24Chemical Stability of Disposables 25Chemical Stability of Disposables 26Chemical Stability of Disposables 27Chemical Stability of Disposables 28Chemical Stability of Disposables 29Chemical Stability of Disposables 30Chemical Stability of Disposables 31
(Date:9/29/2014)... Oktoberfest is here, and that means ... for a cold one, taking that first ... chemicals have reacted to form compounds that ... Reactions explains why beers get skunky, and ... brews from going bad. Learn all about ...
(Date:9/29/2014)... available in French . ... number of days an expectant mother was deprived of ... profile of her child, a new study finds., Scientists ... University have detected a distinctive ,signature, in the DNA ... Quebec ice storm. Five months after the event, researchers ...
(Date:9/29/2014)... researchers at the University of Cambridge has shown that ... most of Greenland is more sensitive to climate change ... rising sea levels that threaten coastal communities worldwide. , ... levels of meltwater created and spilled into the ocean ... new model also takes into account the role that ...
Breaking Biology News(10 mins):Greenland Ice Sheet more vulnerable to climate change than previously thought 2Greenland Ice Sheet more vulnerable to climate change than previously thought 3
... campus of The Scripps Research Institute have uncovered a ... cell death, a characteristic of neurodegenerative diseases such as ... In the study, published recently in the journal ... could disrupt a specific interaction of a critical enzyme ...
... A multicenter clinical trial led by a researcher at ... Center will evaluate a new approach to treat triple-negative ... more common among African-Americans and young women. The study ... can reprogram tumor cells to express a protein called ...
... A new study concludes that models may be ... too high or too low, depending on the region, ... affect the amount of carbon released from soil. ... estimates of greenhouse gas emissions from soils based on ...
Cached Biology News:Scripps Research scientists find way to block stress-related cell death 2New clinical trial to test novel approach to treat triple-negative breast cancer 2New clinical trial to test novel approach to treat triple-negative breast cancer 3Climate projections don't accurately reflect soil carbon release 2Climate projections don't accurately reflect soil carbon release 3
NATIVE, ENZYME PORCINE TRYPSIN...
See product name for description....
Mycoplasma tested...
... Cloning Checker Kits provide two highly efficient ... without time-consuming plasmid preparation. By using the ... you need to do is to transfer ... from the transformation plates into the solutions ...
Biology Products: